Navigation Links
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Date:12/12/2007

SAN CARLOS, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced dosing of the first patient in a Phase 2 proof-of-concept trial of alfimeprase for the treatment of acute ischemic stroke.

Nuvelo has also been granted fast track designation by the U.S. Food and Drug Administration (FDA) for alfimeprase in this indication. Fast track designation, which was mandated by the FDA Modernization Act of 1997, can potentially facilitate expedited review of a Biologics License Application (BLA). Fast track designation is reserved for new drugs that demonstrate the potential to address an unmet medical need and are intended for the treatment of a serious or life-threatening condition.

The Phase 2 CARNEROS-1 (Catheter Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke) proof-of-concept trial is a multi-center, open-label, two part, dose escalation (1 mg, 5 mg and 10 mg) study that will enroll approximately 100 patients within 3-9 hours of stroke onset. CARNEROS-1 is designed to evaluate the safety and efficacy of intra-arterial, catheter-directed, bolus alfimeprase. The primary efficacy endpoint is recanalization, or unblocking, of the primary arterial occlusive lesion within 120 minutes of treatment with alfimeprase. Safety will be assessed, including the rate of symptomatic intracerebral hemorrhages at 24 hours.

"We believe that a safer, more efficacious intra-arterial therapy can change the treatment paradigm for stroke patients and that a product candidate such as alfimeprase holds the potential to restore flow rapidly and expand the current treatment window for this underserved patient population," said Michael Levy, M.D., executive vice preside
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
4. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
5. Enrollment Begins on Human PK Study for Medidur(TM) FA
6. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... it comes to welcoming our new robot overlords, InformationWeek editor ... red carpet. Healthcare is one of the major ... our human sphere. With healthcare concerns top of mind in ... new technologies to help with old problems. That,s where robots ... to increase from $1.7 billion now to $3.7 billion by ...
(Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
(Date:7/23/2014)... LOS ANGELES , July 23, 2014  Researchers ... supplementing with calcium elevates calcium levels too ... stones, among other health problems. Women close ... calcium and vitamin D to prevent diseases such as ... "I would recommend that women determine how much calcium ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Women Taking Too Much Calcium Create Health Risk 2
... Nov. 8, 2010 GenVec, Inc. (Nasdaq: GNVC ) ... 30, 2010.   GenVec reported a net loss of ... 30, 2010 compared to a net loss of $3.6 million ($0.04 ... months ended September 30, 2010, GenVec,s net loss was $11.3 million ...
... 8, 2010 XStor Medical Systems, Inc. announces the ... quality management system certification is a key step in ... globally. "XStor,s software products are designed under ... codifies our ability to deliver safe & effective solutions. ...
Cached Medicine Technology:GenVec Reports Third Quarter 2010 Financial Results 2GenVec Reports Third Quarter 2010 Financial Results 3GenVec Reports Third Quarter 2010 Financial Results 4GenVec Reports Third Quarter 2010 Financial Results 5
(Date:7/23/2014)... Recently, iFitDress.com, a professional company of women’s dresses ... vintage party dresses . Aside from that, it has ... is up to 63% off. , “We are excited to ... items are all manufactured by trustworthy and experienced workers in ... 30; it is great to provide such a great opportunity ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 A new ... a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally ... cancers throughout a woman’s body, Bernstein Liebhard LLP reports. ... the Journal of the American Medical Association, looked at ... morcellator at 500 U.S. hospitals from 2006 to 2012. ...
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Home ... in-home care for seniors, is proud to announce the ... featuring experts in a wide range of health and ... social worker and award-winning author Nancy Kriseman, and will ... ways to prevent burnout by becoming more self-aware. In ...
(Date:7/23/2014)... body of research suggesting a safe and effective ... breast cancer, with fewer detrimental side effects and ... The study will be published in final format ... and Endocrinology . , Breast cancer is the ... United States. Approximately 70% of breast cancers are ...
Breaking Medicine News(10 mins):Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... News) -- Older women who take nonsteroidal anti-inflammatory drugs -- ... lower risk of death from colorectal cancer than women who ... Women who reported using these drugs, called NSAIDs, at the ... roughly 30 percent lower rate of death from colorectal cancer ...
... OCTOBER 24, 2011) Heavy alcohol consumption may be ... while higher BMI and increased consumption of black tea ... deadly disease. In three separate studies presented at CHEST ... of Chest Physicians (ACCP), heavy alcohol consumption was related ...
... safe and effective therapy, according to a new long-term ... co-hosted by the Heart and Stroke Foundation and the ... Ottawa Heart Institute heart transplant program revealed results from ... transplant patients. Mean age at transplant was 49 13 ...
... Postmenopausal women who reported having used nonsteroidal anti-inflammatory drugs ... enrollment in the Women,s Health Initiative study had a ... women who reported no use of these drugs at ... International Conference on Frontiers in Cancer Prevention Research, held ...
... October 23, 2011 -- A new study conducted in an ... called "lazy eye," can be achieved in many older children, ... games along with standard amblyopia treatment. Today at the 115th ... Ghosh will report on the approaches that allowed about a ...
... rehabilitation boosts longevity, especially in patients with the lowest ... Cardiovascular Congress 2011, co-hosted by the Heart and Stroke ... benefits to cardiac rehabilitation, regardless of how fit ... cardiac surgery resident and PhD candidate at the University ...
Cached Medicine News:Health News:Can NSAIDs Cut Colorectal Cancer Deaths in Older Women? 2Health News:Heavy alcohol consumption linked to lung cancer 2Health News:Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades 2Health News:Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades 3Health News:NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women 2Health News:Video games used in new treatment that may fix 'lazy eye' in older children 2Health News:Rehab helps heart patients live longer -- but they have to show up 2Health News:Rehab helps heart patients live longer -- but they have to show up 3
... Ultrapure MB Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing ... Gel Point (1.5%): 36.0 1.5C Remelt Point ... than or equal to 1,200 gm/cm 2 ... 2,500 gm/cm 2 Moisture: less than or ...
... traces: chloride (Cl) ≤ 3000 mg/kg sulfate (SO 4 ... mg/kg Cd ≤ 10 mg/kg Co ≤ 10 mg/kg ... ≤ 10 mg/kg K ≤ 500 mg/kg Mg ≤ ... mg/kg Ni ≤ 10 mg/kg Pb ≤ 10 mg/kg ...
... a multipurpose agarose, has been developed for ... and separation of high molecular weight DNA ... a high gel strength agarose ( 1800 ... the use of low concentrations of agarose ...
Inquire...
Medicine Products: